{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T14:49:34Z","timestamp":1790434174929,"version":"4.1.0"},"reference-count":55,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1178896"],"award-info":[{"award-number":["APP1178896"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Despite the availability of an effective, live attenuated yellow fever virus (YFV) vaccine (YFV 17D), this flavivirus still causes up to \u224860,000 deaths annually. A number of new approaches are seeking to address vaccine supply issues and improve safety for the immunocompromised vaccine recipients. Herein we describe an adult female IFNAR-\/- mouse model of YFV 17D infection and disease that recapitulates many features of infection and disease in humans. We used this model to evaluate a new YFV vaccine that is based on a recently described chimeric Binjari virus (BinJV) vaccine technology. BinJV is an insect-specific flavivirus and the chimeric YFV vaccine (BinJ\/YFV-prME) was generated by replacing the prME genes of BinJV with the prME genes of YFV 17D. Such BinJV chimeras retain their ability to replicate to high titers in C6\/36 mosquito cells (allowing vaccine production), but are unable to replicate in vertebrate cells. Vaccination with adjuvanted BinJ\/YFV-prME induced neutralizing antibodies and protected mice against infection, weight loss and liver pathology after YFV 17D challenge.<\/jats:p>","DOI":"10.3390\/vaccines8030368","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T10:45:19Z","timestamp":1594291519000},"page":"368","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["A Yellow Fever Virus 17D Infection and Disease Mouse Model Used to Evaluate a Chimeric Binjari-Yellow Fever Virus Vaccine"],"prefix":"10.3390","volume":"8","author":[{"given":"Kexin","family":"Yan","sequence":"first","affiliation":[{"name":"Inflammation Biology Group, QIMR Berghofer Medical Research Institute, Brisbane 4029, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7587-2936","authenticated-orcid":false,"given":"Laura J.","family":"Vet","sequence":"additional","affiliation":[{"name":"School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia 4072, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Tang","sequence":"additional","affiliation":[{"name":"Inflammation Biology Group, QIMR Berghofer Medical Research Institute, Brisbane 4029, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0139-9829","authenticated-orcid":false,"given":"Jody","family":"Hobson-Peters","sequence":"additional","affiliation":[{"name":"School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia 4072, Australia"},{"name":"Australian Infectious Disease Research Centre, Brisbane 4029, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7248-0101","authenticated-orcid":false,"given":"Daniel J.","family":"Rawle","sequence":"additional","affiliation":[{"name":"Inflammation Biology Group, QIMR Berghofer Medical Research Institute, Brisbane 4029, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuy T.","family":"Le","sequence":"additional","affiliation":[{"name":"Inflammation Biology Group, QIMR Berghofer Medical Research Institute, Brisbane 4029, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0396-3190","authenticated-orcid":false,"given":"Thibaut","family":"Larcher","sequence":"additional","affiliation":[{"name":"Institut National de Recherche Agronomique, Unit\u00e9 Mixte de Recherche 703, Oniris, Nantes CEDEX 03, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy A.","family":"Hall","sequence":"additional","affiliation":[{"name":"School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia 4072, Australia"},{"name":"Australian Infectious Disease Research Centre, Brisbane 4029, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8986-9025","authenticated-orcid":false,"given":"Andreas","family":"Suhrbier","sequence":"additional","affiliation":[{"name":"Inflammation Biology Group, QIMR Berghofer Medical Research Institute, Brisbane 4029, Australia"},{"name":"Australian Infectious Disease Research Centre, Brisbane 4029, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,9]]},"reference":[{"key":"ref_1","unstructured":"(2019, May 07). WHO Fact Sheet; Yellow Fever. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/yellow-fever."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12985-019-1277-7","article-title":"Recent sylvatic yellow fever virus transmission in Brazil: The news from an old disease","volume":"17","author":"Silva","year":"2020","journal-title":"Virol. J."},{"key":"ref_3","unstructured":"(2020, July 08). Eliminate Yellow Fever Epidemics by 2026, WHO Website. Available online: https:\/\/www.who.int\/csr\/disease\/yellowfev\/eye-strategy-one-pager.pdf."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40794-020-0101-0","article-title":"Yellow fever control: Current epidemiology and vaccination strategies","volume":"6","author":"Chen","year":"2020","journal-title":"Trop. Dis. Travel Med. Vaccines"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Roukens, A.H.E., and Visser, L.G. (2019). Fractional-dose yellow fever vaccination: An expert review. J. Travel Med., 26.","DOI":"10.1093\/jtm\/taz024"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.actatropica.2018.03.009","article-title":"Current status, challenges and perspectives in the development of vaccines against yellow fever, dengue, Zika and chikungunya viruses","volume":"182","author":"Silva","year":"2018","journal-title":"Acta Trop."},{"key":"ref_7","unstructured":"(2020, February 17). Clinical Update Announcement: Temporary Total Depletion of US Licensed Yellow Fever Vaccine Addressed by Availability of Stamaril Vaccine at Selected Clinics, Available online: https:\/\/wwwnc.cdc.gov\/travel\/news-announcements\/yellow-fever-vaccine-access."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.vaccine.2019.12.018","article-title":"Immunogenicity and safety of fractional dose yellow fever vaccination: A systematic review and meta-analysis","volume":"38","author":"Nnaji","year":"2020","journal-title":"Vaccine"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1016\/j.vaccine.2006.01.009","article-title":"Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil","volume":"24","author":"Engel","year":"2006","journal-title":"Vaccine"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Watson, A.M., and Klimstra, W.B. (2017). T Cell-Mediated Immunity towards Yellow Fever Virus and Useful Animal Models. Viruses, 9.","DOI":"10.3390\/v9040077"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Watson, A.M., Lam, L.K., Klimstra, W.B., and Ryman, K.D. (2016). The 17D-204 Vaccine Strain-Induced Protection against Virulent Yellow Fever Virus Is Mediated by Humoral Immunity and CD4+ but not CD8+ T Cells. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005786"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1080\/21645515.2015.1016666","article-title":"Cell culture-based influenza vaccines: A necessary and indispensable investment for the future","volume":"11","author":"Hegde","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_13","unstructured":"(2020, July 08). CDC Vaccine Information Statement. Yellow Fever, Available online: https:\/\/www.cdc.gov\/vaccines\/hcp\/vis\/vis-statements\/yf.html."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Volkov, L., Grard, G., Bollaert, P.E., Durand, G.A., Cravoisy, A., Conrad, M., Nace, L., Courte, G., Marnai, R., and Leparc-Goffart, I. (2020). Viscerotropic disease and acute uveitis following yellow fever vaccination: A case report. BMC Infect. Dis., 20.","DOI":"10.1186\/s12879-020-4838-x"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Domingo, C., Lamerz, J., Cadar, D., Stojkovic, M., Eisermann, P., Merle, U., Nitsche, A., and Schnitzler, P. (2020). Severe Multiorgan Failure Following Yellow Fever Vaccination. Vaccines, 8.","DOI":"10.3390\/vaccines8020249"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Tomashek, K.M., Challberg, M., Nayak, S.U., and Schiltz, H.F. (2019). Disease Resurgence, Production Capability Issues and Safety Concerns in the Context of an Aging Population: Is There a Need for a New Yellow Fever Vaccine?. Vaccines, 7.","DOI":"10.3390\/vaccines7040179"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1009303","article-title":"An inactivated cell-culture vaccine against yellow fever","volume":"364","author":"Monath","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1016\/j.vaccine.2019.04.077","article-title":"Purification of yellow fever virus produced in Vero cells for inactivated vaccine manufacture","volume":"37","author":"Pato","year":"2019","journal-title":"Vaccine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.3389\/fimmu.2018.01756","article-title":"Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model","volume":"9","author":"Julander","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"7061","DOI":"10.1016\/j.vaccine.2019.05.066","article-title":"Purification of flavivirus VLPs by a two-step chomatographic process","volume":"37","author":"Lima","year":"2019","journal-title":"Vaccine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/JVI.77.2.813-820.2003","article-title":"Role of the transmembrane domains of prM and E proteins in the formation of yellow fever virus envelope","volume":"77","author":"Molenkamp","year":"2003","journal-title":"J. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Hurtado-Monzon, A.M., Cordero-Rivera, C.D., Farfan-Morales, C.N., Osuna-Ramos, J.F., De Jesus-Gonzalez, L.A., Reyes-Ruiz, J.M., and Del Angel, R.M. (2020). The role of anti-flavivirus humoral immune response in protection and pathogenesis. Rev. Med. Virol.","DOI":"10.1002\/rmv.2100"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1089\/vim.2019.0107","article-title":"Structure-Function of the Yellow Fever Virus Envelope Protein: Analysis of Antibody Epitopes","volume":"33","author":"Davis","year":"2020","journal-title":"Viral Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Hobson-Peters, J., Harrison, J.J., Watterson, D., Hazlewood, J.E., Vet, L.J., Newton, N.D., Warrilow, D., Colmant, A.M.G., Taylor, C., and Huang, B. (2019). A recombinant platform for flavivirus vaccines and diagnostics using chimeras of a new insect-specific virus. Sci. Transl. Med., 11.","DOI":"10.1126\/scitranslmed.aax7888"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Vet, L.J., Setoh, Y.X., Amarilla, A.A., Habarugira, G., Suen, W.W., Newton, N.D., Harrison, J.J., Hobson-Peters, J., Hall, R.A., and Bielefeldt-Ohmann, H. (2020). Protective Efficacy of a Chimeric Insect-Specific Flavivirus Vaccine against West Nile Virus. Vaccines, 8.","DOI":"10.3390\/vaccines8020258"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1080\/22221751.2019.1694394","article-title":"Limited evolution of the yellow fever virus 17d in a mouse infection model","volume":"8","author":"Kum","year":"2019","journal-title":"Emerg. Microbes Infect."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1099\/vir.0.000075","article-title":"Spectrum of disease outcomes in mice infected with YFV-17D","volume":"96","author":"Erickson","year":"2015","journal-title":"J. Gen. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Meier, K.C., Gardner, C.L., Khoretonenko, M.V., Klimstra, W.B., and Ryman, K.D. (2009). A mouse model for studying viscerotropic disease caused by yellow fever virus infection. PLoS Pathog., 5.","DOI":"10.1371\/journal.ppat.1000614"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.4049\/jimmunol.178.12.7540","article-title":"Type I IFN contributes to NK cell homeostasis, activation, and antitumor function","volume":"178","author":"Swann","year":"2007","journal-title":"J. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/s41467-018-03662-6","article-title":"A vaccinia-based single vector construct multi-pathogen vaccine protects against both Zika and chikungunya viruses","volume":"9","author":"Prow","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0166-0934(94)00136-5","article-title":"Complete removal of mycoplasma from viral preparations using solvent extraction","volume":"52","author":"Bellett","year":"1995","journal-title":"J. Virol. Methods"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1074\/jbc.M411569200","article-title":"Heat shock protein 10 inhibits lipopolysaccharide-induced inflammatory mediator production","volume":"280","author":"Johnson","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"8021","DOI":"10.1128\/JVI.02603-09","article-title":"Chikungunya virus arthritis in adult wild-type mice","volume":"84","author":"Gardner","year":"2010","journal-title":"J. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Setoh, Y.X., Prow, N.A., Peng, N., Hugo, L.E., Devine, G., Hazlewood, J.E., Suhrbier, A., and Khromykh, A.A. (2017). De Novo Generation and Characterization of New Zika Virus Isolate Using Sequence Data from a Microcephaly Case. mSphere, 2.","DOI":"10.1128\/mSphereDirect.00190-17"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Hughes, H.R., Russell, B.J., Mossel, E.C., Kayiwa, J., Lutwama, J., and Lambert, A.J. (2018). Development of a Real-Time Reverse Transcription-PCR Assay for Global Differentiation of Yellow Fever Virus Vaccine-Related Adverse Events from Natural Infections. J. Clin. Microbiol., 56.","DOI":"10.1128\/JCM.00323-18"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.4049\/jimmunol.0902187","article-title":"A physiological function of inflammation-associated SerpinB2 is regulation of adaptive immunity","volume":"184","author":"Schroder","year":"2010","journal-title":"J. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.virol.2005.09.058","article-title":"Revisiting the liver in human yellow fever: Virus-induced apoptosis in hepatocytes associated with TGF-beta, TNF-alpha and NK cells activity","volume":"345","author":"Quaresma","year":"2006","journal-title":"Virology"},{"key":"ref_38","first-page":"177","article-title":"Human fatal yellow fever. Immunohistochemical detection of viral antigens in the liver, kidney and heart","volume":"188","author":"Siqueira","year":"1992","journal-title":"Pathol. Res. Pract."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2559.1983.tb02235.x","article-title":"Histopathology of the human liver in yellow fever with special emphasis on the diagnostic role of the Councilman body","volume":"7","author":"Vieira","year":"1983","journal-title":"Histopathology"},{"key":"ref_40","first-page":"202","article-title":"Clinical biochemistry parameters in C57BL\/6J mice after blood collection from the submandibular vein and retroorbital plexus","volume":"49","author":"Fernandez","year":"2010","journal-title":"J. Am. Assoc. Lab. Anim. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.antiviral.2006.08.008","article-title":"Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on yellow fever virus infection in a hamster model","volume":"73","author":"Julander","year":"2007","journal-title":"Antivir. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1086\/344180","article-title":"A Belgian traveler who acquired yellow fever in the Gambia","volume":"35","author":"Colebunders","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e190033","DOI":"10.1590\/0074-02760190033","article-title":"Lipase and factor V (but not viral load) are prognostic factors for the evolution of severe yellow fever cases","volume":"114","author":"Casadio","year":"2019","journal-title":"Mem. Inst. Oswaldo Cruz."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.clim.2017.08.004","article-title":"Adjuvant formulations for virus-like particle (VLP) based vaccines","volume":"183","author":"Cimica","year":"2017","journal-title":"Clin. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/infdis\/jit365","article-title":"Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults \u2265 50 years of age","volume":"208","author":"Chlibek","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.4049\/jimmunol.1400948","article-title":"Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells","volume":"193","author":"Didierlaurent","year":"2014","journal-title":"J. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Vratskikh, O., Stiasny, K., Zlatkovic, J., Tsouchnikas, G., Jarmer, J., Karrer, U., Roggendorf, M., Roggendorf, H., Allwinn, R., and Heinz, F.X. (2013). Dissection of antibody specificities induced by yellow fever vaccination. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003458"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3389\/fmicb.2020.00245","article-title":"Yellow Fever Vaccination in a Mouse Model Is Associated with Uninterrupted Pregnancies and Viable Neonates Except When Administered at Implantation Period","volume":"11","author":"Magaldi","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Goh, G.K., Dunker, A.K., Foster, J.A., and Uversky, V.N. (2019). Zika and Flavivirus Shell Disorder: Virulence and Fetal Morbidity. Biomolecules, 9.","DOI":"10.3390\/biom9110710"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.3389\/fimmu.2019.03083","article-title":"Granzyme A in Chikungunya and Other Arboviral Infections","volume":"10","author":"Schanoski","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.celrep.2019.01.036","article-title":"Flavivirus NS1 Triggers Tissue-Specific Vascular Endothelial Dysfunction Reflecting Disease Tropism","volume":"26","author":"Glasner","year":"2019","journal-title":"Cell Rep."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Heinz, F.X., and Stiasny, K. (2017). The Antigenic Structure of Zika Virus and Its Relation to Other Flaviviruses: Implications for Infection and Immunoprophylaxis. Microbiol. Mol. Biol. Rev., 81.","DOI":"10.1128\/MMBR.00055-16"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Lim, X.N., Shan, C., Marzinek, J.K., Dong, H., Ng, T.S., Ooi, J.S.G., Fibriansah, G., Wang, J., Verma, C.S., and Bond, P.J. (2019). Molecular basis of dengue virus serotype 2 morphological switch from 29 degrees C to 37 degrees C. PLoS Pathog., 15.","DOI":"10.1371\/journal.ppat.1007996"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41590-018-0210-3","article-title":"The immune response against flaviviruses","volume":"19","author":"Mongkolsapaya","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/s41564-019-0399-4","article-title":"Determinants of Zika virus host tropism uncovered by deep mutational scanning","volume":"4","author":"Setoh","year":"2019","journal-title":"Nat. Microbiol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/3\/368\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:49:33Z","timestamp":1760176173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/3\/368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,9]]},"references-count":55,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["vaccines8030368"],"URL":"https:\/\/doi.org\/10.3390\/vaccines8030368","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,9]]}}}